CN103340884A - Wettable fenbendazole ivermectin powder - Google Patents
Wettable fenbendazole ivermectin powder Download PDFInfo
- Publication number
- CN103340884A CN103340884A CN201310302905XA CN201310302905A CN103340884A CN 103340884 A CN103340884 A CN 103340884A CN 201310302905X A CN201310302905X A CN 201310302905XA CN 201310302905 A CN201310302905 A CN 201310302905A CN 103340884 A CN103340884 A CN 103340884A
- Authority
- CN
- China
- Prior art keywords
- parts
- fenbendazole
- ivermectin
- sodium
- wettability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 title claims abstract description 68
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 title claims abstract description 68
- 229960002418 ivermectin Drugs 0.000 title claims abstract description 68
- 229960005473 fenbendazole Drugs 0.000 title claims abstract description 57
- IRHZVMHXVHSMKB-UHFFFAOYSA-N fenbendazole Chemical compound [CH]1C2=NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 IRHZVMHXVHSMKB-UHFFFAOYSA-N 0.000 title claims abstract description 55
- 239000000843 powder Substances 0.000 title claims abstract description 52
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims abstract description 15
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 15
- 235000013336 milk Nutrition 0.000 claims abstract description 15
- 239000008267 milk Substances 0.000 claims abstract description 15
- 210000004080 milk Anatomy 0.000 claims abstract description 15
- 229940085605 saccharin sodium Drugs 0.000 claims abstract description 15
- 239000001509 sodium citrate Substances 0.000 claims abstract description 15
- 239000000230 xanthan gum Substances 0.000 claims abstract description 15
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 15
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 15
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 18
- 235000011083 sodium citrates Nutrition 0.000 claims description 14
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 14
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical class [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 12
- 241000238421 Arthropoda Species 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000005645 nematicide Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 3
- 208000030852 Parasitic disease Diseases 0.000 claims description 2
- 239000000921 anthelmintic agent Substances 0.000 claims description 2
- 238000011017 operating method Methods 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract description 3
- 241000282887 Suidae Species 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 abstract 2
- 230000035622 drinking Effects 0.000 abstract 1
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 235000019640 taste Nutrition 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 description 13
- 239000005660 Abamectin Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 241000244188 Ascaris suum Species 0.000 description 5
- 230000000507 anthelmentic effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 206010000351 Acariasis Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 201000002266 mite infestation Diseases 0.000 description 3
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 3
- 229960004816 moxidectin Drugs 0.000 description 3
- -1 slow release bolus Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 229930192734 Avilamycin Natural products 0.000 description 1
- 239000004190 Avilamycin Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000242594 Platyhelminthes Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 229960005185 avilamycin Drugs 0.000 description 1
- 235000019379 avilamycin Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 description 1
- 229960002346 eprinomectin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 description 1
- 229960002245 selamectin Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides wettable fenbendazole ivermectin powder which is prepared from the following raw materials and auxiliary materials in parts by weight: 2.5-10 parts of fenbendazole, 0.1-0.8 part of ivermectin, 0.5-3 parts of magnesium stearate, 43.9-74 parts of powdered sugar, 3-11 parts of sodium dodecyl sulfate, 0-8 parts of xanthan gum, 0.6-1 part of fresh milk essence, 0.6-1 part of saccharin sodium and 10-30 parts of sodium citrate. The invention also provides a preparation method and application of the wettable fenbendazole ivermectin powder. The wettable fenbendazole ivermectin powder significantly improves the dispersity of the ivermectin and fenbendazole in water to ensure that the ivermectin and the fenbendazole can be uniformly distributed in the water for a long time to facilitate clinical water drinking and administration; and wettable fenbendazole ivermectin powder has a food calling function, namely that the fenbendazole ivermectin powder has a food calling function when used on faunas with sensitive tastes, such as pigs and the like. The wettable fenbendazole ivermectin powder is simple in preparation process, low in production cost and suitable for industrial large-scale production.
Description
Technical field
The present invention relates to a kind of wettability fenbendazole ivermectin powder and its production and use.
Background technology
Since the forties in 20th century, the research and development of anthelmintic are burning hot unusual always, obtain gratifying achievement therebetween; Particularly 1976 Avermectins medicine (Avermectins) discovery, opened new era of anthelmintic research especially.This compounds has the extremely strong effect of killing to nematicide and the arthropod that parasitizes animal, thereby makes anthelmintic medicine dosage drop to μ g/kg level by the mg/kg level.Commercial in this class medicine at present have an avilamycin (Avermectin, AVM), ivermectin (Ivermectin, IVM), doractin (Doramectin, DRM), acetylamino evericin (Eprinomectin, EPM has another name called her and composes rhzomorph, Ai Purui rhzomorph), match draw rhzomorph (Selamectin, SLM) and moxidectin (Moxidectin or Milbemycin, MXD has another name called Moses Dinke, moxidectin) etc.Because its excellent anthelmintic activity and higher safety, Avermectins medicine is regarded as the best, most widely used anthelmintic for animals at present, is the most outstanding achievement in research in the anti-parasite medicine research in recent years; But good medicine is still needed and is mixed with good preparation its drug effect is given full play to.Therefore be a focus content of new veterinary drug research in the last few years to the preparation research of such medicine and exploitation.AVM powder, tablet, capsule, injection and dashing agent have been developed out now, IVM powder, tablet, paste, oral liquid, slow release bolus, injection and dashing agent, injection and the dashing agent of doractin injection and dashing agent and Ai Purui rhzomorph.
Because Avermectins medicine is never poison, its mechanism is the GABA receptor that acts on parasite synapse or neuromuscular synapse, disturbs the information transmission of teleneuron in the polypide, causes that finally the polypide paralysis is dead.And there is not GABA mediator as neural impulse in polypide such as platyhelminthes, antibacterial and actinomycetes and the thalline, so Avermectins has the Strong pest-expellant effect to nematicide and epizoa and other arthropod, but very little to the effect of trematodiasis, cestode, or do not have an active function.Facts have proved, anti-trematodiasis, cestodes such as Avermectins and fenbendazole are acted on compatibility of drugs use preferably, can remedy the deficiency of two kinds of medicines on pest-resistant spectrum, make its pest-resistant spectrum wider, usefulness is higher, alleviates people for driving away the trouble of multiple parasite multiple dosing simultaneously.Commercial Related product has fenbendazole ivermectin sheet etc. on China market.Though these preparations have satisfied the demand that enlarges pest-resistant spectrum,, in clinical practice, but exist jumpbogroup animals administer difficulty, be difficult to mix homogeneously or shortcoming that can't mix homogeneously with feedstuff.Therefore, when clinical practice, usually medicine is inhomogeneous unsatisfactory curative effect to be occurred or side reaction occurs and even situation such as poisoning animal because taking in.For fear of the generation of this situation, it is very necessary to develop a kind of Avermectins and fenbendazole compound product that is easy to even administration.
The present invention is directed to existing Avermectins and the awkward shortcoming of fenbendazole compound product, provide a kind of and be dispersed in the water, by drinking water or being sprayed at the fenbendazole ivermectin powder of the mode administration on the feedstuff.
Summary of the invention
The object of the present invention is to provide a kind of wettability fenbendazole ivermectin powder, and its production and use.
The invention provides a kind of wettability fenbendazole ivermectin powder, it is that supplementary material by following weight proportion is prepared from:
2.5～10 parts of fenbendazoles, 0.1～0.8 part of ivermectin, 0.5～3 part of magnesium stearate, 43.9～74 parts of Icing Sugar, 3～11 parts of sodium lauryl sulphates, 0～8 part of xanthan gum, 0.6～1 part of fresh milk essence, 0.6～1 part of saccharin sodium, 10～30 parts of sodium citrates.
Wherein, it is that supplementary material by following weight proportion is prepared from:
2.5～5 parts of fenbendazoles, 0.2～0.8 part of ivermectin, 0.5～2.5 part of magnesium stearate, 54.5～74 parts of Icing Sugar, 3～9 parts of sodium lauryl sulphates, 2～8 parts of xanthan gum, 0.6～0.9 part of fresh milk essence, 0.6～0.9 part of saccharin sodium, 10～25 parts of sodium citrates.
Further, it is that supplementary material by following weight proportion is prepared from:
3～5 parts of fenbendazoles, 0.2～0.6 part of ivermectin, 1.5～2.5 parts of magnesium stearate, 54.5～67.5 parts of Icing Sugar, 5～9 parts of sodium lauryl sulphates, 2～6 parts of xanthan gum, 0.7～0.9 part of fresh milk essence, 0.7～0.9 part of saccharin sodium, 15～25 parts of sodium citrates.
Further, it is that supplementary material by following weight proportion is prepared from:
4～5 parts of fenbendazoles, 0.2～0.4 part of ivermectin, 2～2.5 parts of magnesium stearate, Icing Sugar 54.5～61,7～9 parts of sodium lauryl sulphates, 2～4 parts of xanthan gum, 0.8～0.9 part of fresh milk essence, 0.8～0.9 part of saccharin sodium, 20～25 parts of sodium citrates.
Preferably, it is that supplementary material by following weight proportion is prepared from:
4 parts of fenbendazoles, 0.4 part of ivermectin, 2 parts of magnesium stearate, 61 parts of Icing Sugar, 7 parts of sodium lauryl sulphates, 4 parts of xanthan gum, 0.8 part of fresh milk essence, 0.8 part of saccharin sodium, 20 parts of sodium citrates;
Or, 5 parts of fenbendazoles, 0.2 part of ivermectin, 2.5 parts of magnesium stearate, 54.5 parts of Icing Sugar, 9 parts of sodium lauryl sulphates, 2 parts of xanthan gum, 0.9 part of fresh milk essence, 0.9 part of saccharin sodium, 25 parts of sodium citrates.
The present invention also provides the preparation method of above-mentioned wettability fenbendazole ivermectin powder, and it comprises following operating procedure:
(1) takes by weighing supplementary material by weight ratio;
(2) with behind the various supplementary material mixings, be crushed to 200 orders, namely get wettability fenbendazole ivermectin powder.
The present invention also provides the purposes of above-mentioned wettability fenbendazole ivermectin powder in preparation anthelmintic drug for animals.
Further, described medicine is the medicine of control nematicide or arthropod parasitic disease.
Preferably, described nematicide is ascarid; Described arthropod is acarid.
Wettability fenbendazole ivermectin powder of the present invention has significantly improved ivermectin and the fenbendazole dispersibility in water, and it is evenly distributed in the water for a long time, convenient clinical drinking-water administration; Increase luring function, the faunichron that be used for olfactory sensation such as pig, has a sharp sense of taste there is luring function; Preparation technology of the present invention is simple, and low production cost is fit to industrialized great production.
The present invention is described in further detail below in conjunction with the specific embodiment.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following embodiment, all technology that realizes based on content of the present invention all belong to scope of the present invention.
The specific embodiment
The preparation of embodiment 1 wettability fenbendazole ivermectin powder
Get fenbendazole 4g, ivermectin 0.4g, magnesium stearate 2g, Icing Sugar 61g, sodium lauryl sulphate 7g, xanthan gum 4g, fresh milk essence 0.8g, saccharin sodium 0.8g, sodium citrate 20g, behind above-mentioned supplementary material mix homogeneously, be crushed to 200 purpose impalpable powders, packing namely gets wettability fenbendazole ivermectin powder of the present invention.
The preparation of embodiment 2 wettability fenbendazole ivermectin powder
Get fenbendazole 5g, ivermectin 0.2g, magnesium stearate 2.5g, Icing Sugar 54.5g, sodium lauryl sulphate 9g, xanthan gum 2g, fresh milk essence 0.9g, saccharin sodium 0.9g, sodium citrate 25g, behind above-mentioned supplementary material mix homogeneously, be crushed to 200 purpose impalpable powders, packing namely gets wettability fenbendazole ivermectin powder of the present invention.
The supplementary material compatibility screening of embodiment 3 wettability fenbendazole ivermectin powder
(1) preparation of different formulations product
Get the supplementary material in table 1 prescription, prepare wettability fenbendazole ivermectin powder according to the method for embodiment 1, and estimate quality of each prescription.
The preferred version of table 1 wettability fenbendazole ivermectin powder prescription
(2) quality evaluation of wettability fenbendazole ivermectin powder
Dispersion is estimated: get each 1g of wettability fenbendazole ivermectin powder by 6 preparations of table 1 prescription 1～prescription, drop in the 1000ml drinking water, observe or stir and observe its deployment conditions.Disperse slower and inhomogeneous being chosen as " poor "; Disperse slower, have in the dispersive process caking or granule, agitation as appropriate can be uniformly dispersed, and is chosen as " qualified "; Disperse soon, gentle agitation can be uniformly dispersed, and is chosen as " very "; Disperse to stir and to be uniformly dispersed soon, be chosen as " excellent ".The results are shown in Table 2.
Settling volume is than estimating: by " taking solution orally, take suspensoid orally, take Emulsion orally " settling volume in " People's Republic of China's veterinary drug allusion quotation (version in 2010) " appendix than inspection technique requirement, wettability fenbendazole ivermectin powder by prescription 1～prescription 6 preparations is carried out settling volume than measuring, sample thief 0.25g puts in the 50ml tool plug graduated cylinder, add water to 50ml, fill in close, firmly jolting 1min writes down suspended matter and begins height H
0, leave standstill and write down the final height H of suspended matter in 3 hours, be calculated as follows: settling volume ratio=H/H
0, the settling volume ratio should be not less than 0.90.The results are shown in Table 2.
Table 2 wettability fenbendazole ivermectin opaque amount evaluation result
His-and-hers watches 1 listed 4 indexs are carried out analysis-by-synthesis and can be got: prescription 2～prescription is 6 all qualified, wherein again with fill a prescription 4, prescription 5 is optimum.
Below specify beneficial effect of the present invention by testing example.
The sick therapeutic effect with acariasis to ascaris suum of test example 1 wettability fenbendazole ivermectin powder is investigated
Material: fenbendazole powder (5%, the market sale product); Ivermectin powder (0.2%, the market sale product); Fenbendazole ivermectin powder (5%+0.2%, embodiment 2 preparations).
Case: (sick pig continues to become thin ascaris suum case 48 examples of Chengdu suburbs and counties under the jurisdiction of a large city first pig farm natural occurrence, is off one's feed, and spirit is depressed etc., get the disease swine excrement, carry out the worm's ovum inspection, detect and be the yellowish-brown ellipse, chorion is thicker, and adventitia is rough wavy ascaris suum germ cell); Pig acarid case 56 examples of Person B pig farm, suburb, Chengdu natural occurrence (sick pig becomes thin, down in spirits, and as seen happiness frays the vesicle that occurs behind the skin, incrustation, depilation etc. in wall friction; Collect the scurf of disease pig injury moistening, directly be coated on the microscope slide, can be observed demodicid mite alive).
Method: select the suitable substantially clinical onset growing and fattening pigs of body weight, in same pig house, be divided into matched group, test group and negative control group at random under the identical raising condition; Matched group by 0.2% concentration spice, supplies sick pig feeding with fenbendazole powder+ivermectin powder (1:1 mixing), is used in conjunction 3 days; Test group is converted drinking water with wettability fenbendazole ivermectin powder by 0.05% concentration, drinks for sick pig, is used in conjunction 3 days; Negative control group is raised by daily feeding manner, not administration.
The efficacy determination method: medication is after 5 days, and it is normal that spiritual appetite is recovered, and microscopy does not have parasite alive or worm's ovum, is judged to recovery from illness; After the medication 5 days, spiritual appetite takes a turn for the better, and the visible a small amount of parasite that lives of microscopy is judged to effectively; After the medication 5 days, symptom does not have obvious improvement, and it is invalid to be judged to.
Experimental result: see Table 3, table 4.
Table 3 wettability fenbendazole ivermectin powder is investigated the result to the curative effect of ascaris suum disease
Table 4 wettability fenbendazole ivermectin powder is investigated the result to the curative effect of acariasis
From experimental result as can be seen, wettability fenbendazole ivermectin powder all is better than commercially available fenbendazole ivermectin powder to the sick therapeutic effect with the pig acariasis of ascaris suum; The convenience that wettability fenbendazole ivermectin powder uses is better than commercially available fenbendazole ivermectin powder, reduces the working strength of administration greatly.Find also that in test owing to the mode administration of taking to drink water and add, wettability fenbendazole ivermectin powder does not influence the feed intake of disease pig.
Claims (9)
1. wettability fenbendazole ivermectin powder is characterized in that: it is that supplementary material by following weight proportion is prepared from:
2.5～10 parts of fenbendazoles, 0.1～0.8 part of ivermectin, 0.5～3 part of magnesium stearate, 43.9～74 parts of Icing Sugar, 3～11 parts of sodium lauryl sulphates, 0～8 part of xanthan gum, 0.6～1 part of fresh milk essence, 0.6～1 part of saccharin sodium, 10～30 parts of sodium citrates.
2. wettability fenbendazole ivermectin powder according to claim 1 is characterized in that: it is that supplementary material by following weight proportion is prepared from:
2.5～5 parts of fenbendazoles, 0.2～0.8 part of ivermectin, 0.5～2.5 part of magnesium stearate, 54.5～74 parts of Icing Sugar, 3～9 parts of sodium lauryl sulphates, 2～8 parts of xanthan gum, 0.6～0.9 part of fresh milk essence, 0.6～0.9 part of saccharin sodium, 10～25 parts of sodium citrates.
3. wettability fenbendazole ivermectin powder according to claim 2 is characterized in that: it is that supplementary material by following weight proportion is prepared from:
3～5 parts of fenbendazoles, 0.2～0.6 part of ivermectin, 1.5～2.5 parts of magnesium stearate, 54.5～67.5 parts of Icing Sugar, 5～9 parts of sodium lauryl sulphates, 2～6 parts of xanthan gum, 0.7～0.9 part of fresh milk essence, 0.7～0.9 part of saccharin sodium, 15～25 parts of sodium citrates.
4. wettability fenbendazole ivermectin powder according to claim 3 is characterized in that: it is that supplementary material by following weight proportion is prepared from:
4～5 parts of fenbendazoles, 0.2～0.4 part of ivermectin, 2～2.5 parts of magnesium stearate, Icing Sugar 54.5～61,7～9 parts of sodium lauryl sulphates, 2～4 parts of xanthan gum, 0.8～0.9 part of fresh milk essence, 0.8～0.9 part of saccharin sodium, 20～25 parts of sodium citrates.
5. wettability fenbendazole ivermectin powder according to claim 4 is characterized in that: it is that supplementary material by following weight proportion is prepared from:
4 parts of fenbendazoles, 0.4 part of ivermectin, 2 parts of magnesium stearate, 61 parts of Icing Sugar, 7 parts of sodium lauryl sulphates, 4 parts of xanthan gum, 0.8 part of fresh milk essence, 0.8 part of saccharin sodium, 20 parts of sodium citrates;
Or, 5 parts of fenbendazoles, 0.2 part of ivermectin, 2.5 parts of magnesium stearate, 54.5 parts of Icing Sugar, 9 parts of sodium lauryl sulphates, 2 parts of xanthan gum, 0.9 part of fresh milk essence, 0.9 part of saccharin sodium, 25 parts of sodium citrates.
6. the preparation method of any described wettability fenbendazole ivermectin powder of claim 1～5, it is characterized in that: it comprises following operating procedure:
(1) takes by weighing supplementary material by weight ratio;
(2) with behind the various supplementary material mixings, be crushed to 200 orders, namely get wettability fenbendazole ivermectin powder.
7. any described wettability fenbendazole ivermectin powder of claim 1～5 is in the purposes of preparation in the anthelmintic drug for animals.
8. purposes according to claim 7 is characterized in that: described medicine is the medicine of control nematicide or arthropod parasitic disease.
9. purposes according to claim 8, it is characterized in that: described nematicide is ascarid; Described arthropod is acarid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310302905.XA CN103340884B (en) | 2013-07-18 | 2013-07-18 | Wettable fenbendazole ivermectin powder |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310302905.XA CN103340884B (en) | 2013-07-18 | 2013-07-18 | Wettable fenbendazole ivermectin powder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103340884A true CN103340884A (en) | 2013-10-09 |
| CN103340884B CN103340884B (en) | 2015-07-22 |
Family
ID=49275746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310302905.XA Expired - Fee Related CN103340884B (en) | 2013-07-18 | 2013-07-18 | Wettable fenbendazole ivermectin powder |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103340884B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536624A (en) * | 2013-10-31 | 2014-01-29 | 成都乾坤动物药业有限公司 | Wettable three-ingredient white composition powder and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011408A (en) * | 2007-01-29 | 2007-08-08 | 江西省百思特动物药业有限公司 | Animal-used compound preparation for treating parasitic disease in or out of livestock and fowl body and preparation method thereof |
| CN101268810A (en) * | 2008-05-16 | 2008-09-24 | 赵光政 | Composite prebiotics feed additive |
| CN101375856A (en) * | 2007-08-28 | 2009-03-04 | 天津生机集团有限公司 | Compound ivermectin injection and preparation method |
| CN103083348A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Albendazole/ivermectin powder for livestock |
-
2013
- 2013-07-18 CN CN201310302905.XA patent/CN103340884B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011408A (en) * | 2007-01-29 | 2007-08-08 | 江西省百思特动物药业有限公司 | Animal-used compound preparation for treating parasitic disease in or out of livestock and fowl body and preparation method thereof |
| CN101375856A (en) * | 2007-08-28 | 2009-03-04 | 天津生机集团有限公司 | Compound ivermectin injection and preparation method |
| CN101268810A (en) * | 2008-05-16 | 2008-09-24 | 赵光政 | Composite prebiotics feed additive |
| CN103083348A (en) * | 2012-05-10 | 2013-05-08 | 重庆金邦动物药业有限公司 | Albendazole/ivermectin powder for livestock |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103536624A (en) * | 2013-10-31 | 2014-01-29 | 成都乾坤动物药业有限公司 | Wettable three-ingredient white composition powder and preparation method thereof |
| CN103536624B (en) * | 2013-10-31 | 2016-08-17 | 成都乾坤动物药业有限公司 | A kind of wettable three-ingredient white composition powder and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103340884B (en) | 2015-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340885B (en) | Wettable albendazole ivermectin powder | |
| CN101947202A (en) | Microemulsion for animals and preparation method thereof | |
| CN102845749A (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| CN103191092B (en) | Pharmaceutical composition with effects of supplying calcium and zinc | |
| CN103340884B (en) | Wettable fenbendazole ivermectin powder | |
| CN103417486B (en) | A kind of wettable ivermectin solid dispersion powder and its production and use | |
| CN1969683A (en) | Selenium and zinc enriched health food and preparation process thereof | |
| CN103222975B (en) | Application of enrofloxacin salt in preparation of swine oral preparation | |
| CN103405388B (en) | Wettable moxidectin solid dispersing powder as well as preparation method and application thereof | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN102028677B (en) | Application of juglone in preparation of anti-eimeria tenella medicines | |
| CN103393706A (en) | Wettable ivermectin albendazole oxide powder | |
| WO2015131421A1 (en) | Selenylated tea polyphenol preparation with high content of selenium | |
| CN108186631A (en) | A kind of pharmaceutical composition and its preparation method and application | |
| US10426840B2 (en) | Oil suspension of metronidazole | |
| CN102578451A (en) | Health-care food composite capable of decreasing blood sugar | |
| CN102198099B (en) | Toltrazuril suspension and preparation method thereof | |
| CN102247390B (en) | Medicine for treating bacterial air sacculitis in livestock and preparation method thereof | |
| Quintana et al. | Exposure to toxic metal (loid) s via breastmilk and stunting in infants living in the Lake Atitlán watershed, Guatemala | |
| CN103536606B (en) | A kind of wettable sulfamethoxydiazine powder and preparation method thereof | |
| CN109966289A (en) | Application of the dephnetin in anti-chicken coccidiasis | |
| Kanaeva et al. | Clinical and Experimental Substantiation of The Use of Macrolide Antibiotic in Gastrointestinal and Respiratory Diseases | |
| CN102018687B (en) | Application of hexachlorophene in preparation of anti-eimeria tenella drugs | |
| CN107927798A (en) | A kind of medicinal and edible plant protein powder composition and preparation method thereof | |
| CN103536624B (en) | A kind of wettable three-ingredient white composition powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee after: Chengdu Qiankun animal pharmaceutical Limited by Share Ltd Patentee after: Shanghai Simenon Biotech Co., Ltd. Address before: 611130 Wenjiang, Chengdu, Chengdu cross strait science and Technology Industrial Development Zone, Jin Fu Road, Sichuan Patentee before: Chengdu Qiankun Animal Pharmaceutical Co.,Ltd. Patentee before: Shanghai Simenon Biotech Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150722 Termination date: 20200718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |